by The global Europe Platelet Rich Plasma Market is estimated to be valued at US$ 110.4 Million in 2022 and is expected to exhibit a CAGR of 15.6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Platelet rich plasma is a concentration of human platelets in a small amount of plasma. PRP works as a natural tissue healing drug by helping the body to release growth factors at the injury site and stimulating healing. It is administered locally at the site of injury to accelerate healing. PRP therapy facilitates rapid healing without using drugs or surgery and helps in pain relief.
Market key trends:
One of the key trends in the Europe platelet rich plasma market is increasing adoption of platelet rich plasma therapy for treatment of orthopedic disorders. Platelet rich plasma injections are increasingly being used for treatment of sports injuries, tendinitis, osteoarthritis, and joint pain. PRP acts as a natural tissue healing agent by releasing growth factors at the injury site that stimulate healing. It helps reduce pain and swelling, and enhances tissue regeneration.
Segment Analysis
The Europe Platelet Rich Plasma market is segmented based on type, application and end user. By type, the pure PRP segment dominated the market in 2023 due to its effectiveness in reducing inflammation and promoting tissue regeneration. Pure PRP contains a high concentration of platelets and growth factors that aid healing.
By application, the orthopedic surgery segment accounted for the largest share of the market in 2023. This is because PRP is widely used in orthopedic procedures such as knee, elbow and shoulder injuries to reduce pain and accelerate recovery.
By end user, hospitals and clinics formed the highest revenue generating segment in 2023. This is attributed to the rising number of orthopedic surgeries performed in hospitals and increasing availability of advanced treatment options using PRP therapy.
Key Takeaways
Europe Platelet Rich Plasma Market Size was valued at US$ 110.4 million in 2023 and is expected to witness high growth, exhibiting a CAGR of 15.6% over the forecast period of 2023-2030, due to rising incidence of sports injuries and musculoskeletal disorders.
Regionally, Germany dominated the Europe PRP market in 2023 attributed to growing aging population, increasing healthcare expenditure and adoption of advanced treatment methods. Italy and UK are also among the major revenue generating countries in the region.
The key players operating in the Europe Platelet Rich Plasma market are Vivostat A/S, Estar Medical, CosmoFrance Inc., Kelly Harris Aesthetics, Arthrex, Inc., Terumo Corporation, T-Biotechnology Ltd. St., EmCyte Corporation, Johnson & Johnson Private Limited, Zimmer Biomet, PRP Concepts, ADVACARE PHARMA, Isto Biologics, Arthrex, Inc., Stryker, GLOFINN, Medira Ltd, Regen Lab SA, Estar Technologies Ltd. Major players are focusing on new product launches and strategic collaborations to consolidate their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
